home / stock / ogen / ogen quote
Last: | $1.03 |
---|---|
Change Percent: | -6.86% |
Open: | $1.09 |
Close: | $1.03 |
High: | $1.09 |
Low: | $1.02 |
Volume: | 80,446 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.03 | $1.09 | $1.03 | $1.09 | $1.02 | 80,446 | 07-03-2024 |
$1.02 | $1.04 | $1.02 | $1.04 | $1 | 49,161 | 07-02-2024 |
$1.0601 | $1.06 | $1.0601 | $1.09 | $1.0224 | 45,490 | 07-01-2024 |
$1.04 | $1.01 | $1.04 | $1.055 | $1 | 57,465 | 06-28-2024 |
$0.99 | $1.03 | $0.99 | $1.03 | $0.9701 | 159,982 | 06-27-2024 |
$1.01 | $0.9993 | $1.01 | $1.03 | $0.98 | 133,450 | 06-26-2024 |
$1 | $1.05 | $1 | $1.05 | $0.97 | 344,586 | 06-25-2024 |
$1.305 | $1.5 | $1.305 | $1.5 | $1.25 | 51,234 | 06-24-2024 |
$1.44 | $1.57 | $1.44 | $1.57 | $1.4 | 43,825 | 06-21-2024 |
$1.45 | $1.45 | $1.45 | $1.53 | $1.3332 | 39,419 | 06-20-2024 |
$1.53 | $1.59 | $1.53 | $1.6745 | $1.523 | 16,152 | 06-19-2024 |
$1.53 | $1.59 | $1.53 | $1.6745 | $1.523 | 16,152 | 06-18-2024 |
$1.62 | $1.77 | $1.62 | $1.77 | $1.62 | 11,838 | 06-17-2024 |
$1.64 | $1.6652 | $1.64 | $1.6899 | $1.63 | 10,134 | 06-14-2024 |
$1.69 | $1.68 | $1.69 | $1.75 | $1.66 | 15,772 | 06-13-2024 |
$1.71 | $1.75 | $1.71 | $2.02 | $1.65 | 82,471 | 06-12-2024 |
$1.75 | $1.73 | $1.75 | $1.76 | $1.6909 | 11,524 | 06-11-2024 |
$1.671 | $1.63 | $1.671 | $1.7409 | $1.6263 | 21,946 | 06-10-2024 |
$1.67 | $1.7 | $1.67 | $1.7699 | $1.6617 | 33,163 | 06-07-2024 |
$1.72 | $1.9999 | $1.72 | $1.9999 | $1.6801 | 46,210 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concu...
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock ...